Literature DB >> 26332336

Immunocytochemical p63 expression discriminates between primary cutaneous follicle centre cell and diffuse large B cell lymphoma-leg type, and is of the TAp63 isoform.

Alistair Robson1, Zena Shukur1, Mina Ally2, Justine Kluk1, Kun Liu3, Laura Pincus4, Debjani Sahni5, Uma Sundram6, Antonio Subtil7, Laszlo Karai8, Werner Kempf9, Stefan Schieke10, Philip Coates11.   

Abstract

AIMS: The p63 gene shares structural and functional homologies with the p53 family of transcriptional activators, but differs in exhibiting a consistent expression pattern in normal tissues. Although p63 is rarely mutated in malignancy studies of primary human tumours and cell lines suggest that p63 may promote tumour development. In non-Hodgkin's nodal lymphoma, TAp63 expression in follicular lymphoma (54%) and diffuse large B cell lymphoma (34%) has been described and correlated with the proliferative index. In this study, we analysed a series of primary cutaneous B cell lymphomas for immunohistochemical expression of p63. METHODS AND
RESULTS: Thirty cases of diffuse large B cell lymphoma leg type (pcDLBCLL) and 34 cases of follicle centre cell lymphoma (pcFCCL) were stained using a generic antibody to p63, and a subset of these with an antibody specific for delta-Np63 isoform. The results indicate a significant difference between pcDLBCLL (21 of 30) and pcFCCL (four of 34) in p63 expression (P = 0.000); expression correlated strongly with the proliferation rate as assessed by Ki-67 (P = 0.015). None of the p63((+)) cases tested expressed the delta-Np63 isoform, suggesting that expression is of the TAp63 isoform.
CONCLUSIONS: Functional studies are required to clarify the significance of p63 overexpression in primary cutaneous B cell lymphoma.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  B cell lymphoma; cutaneous; immunohistochemistry; oncogene; p63

Mesh:

Substances:

Year:  2016        PMID: 26332336     DOI: 10.1111/his.12855

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

1.  Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.

Authors:  Xueju Wang; Rebecca L Boddicker; Surendra Dasari; Jagmohan S Sidhu; Marshall E Kadin; William R Macon; Stephen M Ansell; Rhett P Ketterling; Karen L Rech; Andrew L Feldman
Journal:  Hum Pathol       Date:  2017-01-30       Impact factor: 3.466

2.  A Case of p63 Positive Diffuse Large B Cell Lymphoma of the Bladder.

Authors:  Chelsey D Deel; Carol Jones; Teresa Scordino
Journal:  Case Rep Hematol       Date:  2016-08-25

3.  Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience.

Authors:  Wan-Ming Hu; Jie-Tian Jin; Chen-Yan Wu; Jia-Bin Lu; Li-Hong Zhang; Jing Zeng; Su-Xia Lin
Journal:  Diagn Pathol       Date:  2019-11-11       Impact factor: 2.644

4.  p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors.

Authors:  Stefan Steurer; Claudia Riemann; Franziska Büscheck; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Anne Menz; Margit Fisch; Michael Rink; Christian Bernreuther; Patrick Lebok; Till S Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; David Dum; Ronald Simon; Sarah Minner; Eike Burandt; Rainer Krech; Till Krech; Andreas H Marx
Journal:  Biomark Res       Date:  2021-01-25

Review 5.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

Review 6.  New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015-September 2015.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-11-19       Impact factor: 0.196

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.